DexCom, Inc. (DXCM) Stock

Healthcare · Medical Devices · Member of S&P 500, NASDAQ 100

DexCom, Inc. (DXCM) closed at USD 83.47 on 2026-10-14, a change of +20.6 % over the past year, with a market capitalization of USD 33.1B.

DexCom, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

DexCom, Inc. key figures

Previous close

USD 83.47 (2026-10-14)

1-year change

+20.6 %

Market cap

USD 33.1B

Enterprise value

USD 32.55B

P/E ratio (trailing)

33.74

P/E ratio (forward)

28.08

EPS (trailing)

2.60

EPS (forward)

3.12

PEG ratio

2.08

Price to book

12.63

Revenue growth

13.1 %

Earnings growth

43.6 %

Dividend per share (trailing)

0.00

Short ratio

3.52

Employees

11,000

Analyst consensus (third-party)

strong_buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About DexCom, Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States and internationally. The company offers Dexcom G7 and G7 15 Day, an integrated continuous glucose monitoring system; Dexcom G6, a CGM system; Dexcom ONE+ to replace fingerstick blood glucose testing for diabetes treatment decisions; Stelo, a biosensor designed for adults with prediabetes and Type 2 diabetes who do not use insulin; Dexcom Share, a remote monitoring system; and Dexcom Follow application. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for DexCom, Inc. and compare it with other stocks.